EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Track record

Tools

  • Compare
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›ADAG

ADAG

Adagene Inc.

Next earnings Aug 10, 2026 · consensus $-0.14 EPS

Hold
$4.19
▲ +1.70%
$4.19▲ +120.53%
over 1Y
L $1.41EODHDH $4.61
Today+1.7%
1W+9.1%
1M+4.8%
3M+11.1%
YTD+127.7%
1Y+120.5%
OverviewFinancialsValuationQualityFilings
Rating
Hold
Quality
D
Valuation
Fair value
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy

Revenue grew 7332.8% YoY; but unprofitable (net margin -229.6%).

Adagene Inc. shows $7.67M in FY2025 revenue (+7332.8% YoY), a -229.6% net margin, and -49.8% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$10.2M$9.29M$18.1M$103K$7.67M
Gross profit—————
Operating income-$72.4M-$83.9M-$23.7M-$36.0M-$21.4M
Net income-$73.2M-$80.0M-$18.9M-$33.4M-$17.6M
Diluted EPS-$1.46-$1.48-$0.35-$0.59-$0.30
Net margin-719.2%-860.6%-104.6%-32386.4%-229.6%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$176M
EV / EBITDA—
EV / Sales22.9
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-7.1%
FCF yield-6.3%

Quality & risk

ROIC (est.)-45.5%
Free cash flow-$15.7M
Total debt$1.85M
Net cash$72.7M
Altman Z-Score-0.24 distress
Piotroski F-Score4/8

Capital returns

Buyback yield1.6%
Dividend yield (est.)—
Shareholder yield1.6%
Shares Δ YoY+0.6%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
SCHEDULE 13D/AFiling2026-06-08open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-07open ↗6-KPeriod ending 2026-04-172026-04-17open ↗424B5Filing2026-04-02open ↗6-KPeriod ending 2026-04-022026-04-02open ↗424B5Filing2026-04-02open ↗6-KPeriod ending 2026-04-022026-04-02open ↗6-KPeriod ending 2026-04-012026-04-01open ↗20-FPeriod ending 2025-12-312026-04-01open ↗SCHEDULE 13GFiling2026-03-18open ↗3Period ending 2026-03-182026-03-18open ↗

Quality score

D
ValueGrowthProfitHealthMom.
ValueF
GrowthA+
ProfitabilityF
Financial healthC+
Momentum—
  • ✓Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$7.67M
+7332.8% YoY
Net margin
-229.6%
ROE
-49.8%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$7.67M+7332.8%
Net income-$17.6M+47.3%
Operating income-$21.4M+40.4%
Diluted EPS-$0.30+49.2%
Cash & equivalents$74.5M-12.5%
Total assets$78.3M-12.3%
Total liabilities$26.4M-32.0%
Stockholders' equity$35.3M-30.0%
Op.: -279.5%L/E: 0.75x

Frequently asked

Is Adagene Inc. (ADAG) a buy?
ADAG currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 7332.8% YoY; but unprofitable (net margin -229.6%).
What is Adagene Inc.'s quality score?
ADAG scores 47.94117647058823/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001818838, latest SCHEDULE 13D/A filed 2026-06-08) · EODHD · as of 6/27/2026, 9:18:16 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Recent news

market news →
Add Up The Pieces: PGJ Could Be Worth $33Bullish
nasdaq.com· 2026-06-18
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal CancerBullish
finance.yahoo.com· 2026-04-20
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology Collaboration - Has The Bull Case Changed?Bullish
finance.yahoo.com· 2026-04-05
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)Bullish
finance.yahoo.com· 2026-04-02
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)Bullish
globenewswire.com· 2026-04-02
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of ResponseBullish
globenewswire.com· 2026-04-02

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score48 vs 67
Revenue growth7332.8% vs 7.1%
Net margin-229.6% vs 10.5%
Return on equity-49.8% vs 12.3%
P/E— vs 25.5